Login to Your Account

Amgen Boosts Pipeline, Adds SHPT Drug in $315M KAI Buy

By Catherine Shaffer
Staff Writer

Wednesday, April 11, 2012
Wowed by stunning Phase IIa results for nephrology candidate KAI-4169, Thousand Oaks, Calif.-based Amgen Inc. tendered an offer of $315 million in cash to buy KAI Pharmaceuticals Inc., of San Francisco.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription